Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting

  • Updated data from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper gastrointestinal (GI) cancers will be presented in a special ASCO plenary series rapid abstract update session by Yelena Y. Janjigian, M.D., Chief Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, and Lead Investigator for the EDGE-Gastric study
  • Data from ARC-9 evaluating an etrumadenant plus zimberelimab-based treatment combination in third-line metastatic colorectal cancer will be presented in an oral presentation by Zev A. Wainberg, M.D., MSc, Co-Director UCLA Gastrointestinal Oncology Program, and Lead Investigator for the ARC-9 study
  • Trial in Progress (TIP) poster for VELOCITY-Lung Substudy-03, a Phase 2 study of perioperative domvanalimab plus zimberelimab and chemotherapy in patients with resectable Stage II-III non-small cell lung cancer

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced three accepted abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 – June 4, 2024. The selected abstracts presented in partnership with Gilead Sciences provide strong support for the companies’ portfolio of investigational medicines across multiple types of cancer, including lung, upper GI and colorectal cancer.

“We will have two oral presentations for Phase 2 studies that highlight the potential for novel immuno-oncology mechanisms and combinations in gastrointestinal cancers,” said Terry Rosen, Ph.D., chief executive officer of Arcus. “The EDGE-Gastric presentation will include the median progression-free survival (PFS) data for our Fc-silent anti-TIGIT antibody in combination with zimberelimab and chemotherapy in upper GI cancers, the same setting as our STAR-221 Phase 3 study. The ARC-9 presentation will include randomized PFS and overall survival data for an etrumadenant (our adenosine receptor antagonist)-based combination therapy versus regorafenib, an approved standard of care in third-line colorectal cancer.”

Three Accepted Abstracts Will Be Presented

Study

Title

Abstract Number

Session Type &

Title

Session Date

& Time

Domvanalimab (Fc-silent anti-TIGIT monoclonal antibody) plus Zimberelimab (anti-PD-1 antibody)

EDGE-Gastric

Updates on Abstract 433248: EDGE-Gastric Arm A1: Phase 2 study of domvanalimab, zimberelimab, and FOLFOX in first-line (1L) advanced gastroesophageal cancer.

433248

ASCO Plenary Series: Rapid Abstract Updates

6/01/2024,

12:30 PM –

1:30 PM CT

VELOCITY-Lung Substudy-03 TIP

VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom)+zimberelimab (zim)+chemotherapy (chemo) or zim+chemo followed by adjuvant dom+zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC).

TPS8121

Poster Session – Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

6/3/2024,

1:30 PM –

4:30 PM CT

Etrumadenant (A2a/A2b receptor antagonist)

ARC-9

ARC-9: A Randomized Study to Evaluate Etrumadenant-Based Treatment Combinations in Previously Treated Metastatic Colorectal Cancer (mCRC)

3508

Gastrointestinal Cancer—Colorectal and Anal: Oral Abstract Session

6/2/2024,

8:00 AM –

11:00 AM CT

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a, CD39 and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.

Domvanalimab, zimberelimab and etrumadenant are investigational molecules. Neither Gilead nor Arcus has received approval from any regulatory authority for any use of these molecules, and their safety and efficacy for the treatment of gastrointestinal and lung cancers have not been established.

The Arcus name and logo are trademarks of Arcus Biosciences, Inc. All other trademarks belong to their respective owners.

Contacts

Investor Inquiries:

Pia Eaves

VP of Investor Relations & Strategy

(617) 459-2006

peaves@arcusbio.com

Media Inquiries:

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

hkolkey@arcusbio.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.